NCT03509545View on ClinicalTrials.gov

Comparison of Once Daily 40 mg Torsemide With Twice-daily 40 mg Furosemide

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 30, 2021

Primary Completion Date

June 30, 2022

Study Completion Date

June 30, 2022

Conditions
Body Weight Changes
Interventions
DRUG

CHF Patients: ER Torsemide 40 mg

ER Torsemide 40mg given once daily to CHF patients

DRUG

CHF Patients: Furosemide 40 mg

Stable CHF patients taking twice-daily 40 mg Furosemide

Trial Locations (1)

560099

Syngene International, Bangalore

All Listed Sponsors
lead

Sarfez Pharmaceuticals, Inc.

INDUSTRY